Temporal variation in the effects of ophthalmic timolol on cardiovascular and respiratory functions in healthy men

Journal of Clinical Pharmacology

Volumn 37, Issue 1, 1997, Pages 58-63

  Umetsuki, Megumi Hara ^a   Kotegawa, Tsutomu ^a   Nakamura, Koichi ^a   Nakano, Shigeyuki ^a   Nakatsuka, Kazuo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TIMOLOL MALEATE;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR HYPOTENSION; MALE; NORMAL HUMAN; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; SUBCONJUNCTIVAL DRUG ADMINISTRATION;

EID: 0030974877     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009703700110     Document Type: Article

References (26)

1. Van Buskirk EM: Adverse reactions from timolol administration. Ophthalmology 1980;87:447-450.
2. Everitt DE, Avorn J: Systemic effects of medications used to treat glaucoma. Ann Intern Med 1990;112:120-125.
3. Schoene RB, Abuan T, Ward RL, Beasley CH: Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984;97:86-92.
4. McMahon CD, Shaffer RN, Hoskins HD Jr, Hetherington J Jr: Adverse effects experienced by patients taking timolol. Am J Ophthalmol 1979;88:736-738.
5. Woolcock AJ, Peat JK, Salome CM, Yan K, Anderson SD, Schoeffl RE, et al: Prevalence of bronchial hyperresponsiveness and asthma in rural adult population. Thorax 1987;42:361-368.
6. Diggory P, Heyworth P, Chau G, McKenzie S, Sharma A: Unsuspected bronchospasm in association with topical timolol - a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age and Ageing 1994;23:17-21.
7. Langner B, Lemmer B: Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol 1988;33:619-624.
8. Fujimura A, Kumagai Y, Sugimoto K, Kajiyama H, Ebihara A, Ohashi K: Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects. Eur J Clin Pharmacol 1990;38:133-137.
9. Zimmerman TJ, Baumann JD, Hetherington J Jr: Side effects of timolol. Surv Ophthalmol 1983;28:243-249.
10. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. Am J Opthalmol 1986;102:606-611.
11. Ministry of Health and Welfare Japan: Information on Adverse Reactions to Drugs. 1989;94:14-15.
12. McGourty JC, Silas JH, Fleming JJ: Pharmacokinetics and beta blocking effects of timolol in poor and extensive metabolizers of debrisoquine. Clin Pharmacol Ther 1985;38:409-413.
13. Hayashi M, Takase M: Population study of poor debrisoquine-type metabolizers of propranolol among Japanese. Jpn J Opthalmol 1985;29:272-281.
14. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al: Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-408.
15. Al-Sereiti MR, Edeki T, Lledo P, Turner P: The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers. Int J Clin Pharm Res 1990;10:339-345.
16. Kaila T, Karahuvara S, Huupponen R, Iisalo E: The analysis of plasma kinetics and β-receptor binding and -blocking activity of timolol following its small intravenous dose. Int J Clin Pharmacol Ther Toxicol 1993;31:351-357.
17. Affrime MB, Lowenthal DT, Tobert JA, Shirk J, Eidelson B, Cook T, et al: Dynamics and kinetics of ophthalmic timolol. Clin Pharmacol Ther 1980;27:471-477.
18. Doyle WJ, Weber PA, Meeks RH: Effect of topical timolol maleate on exercise performance. Arch Ophthalmol 1984; 102:1517-1518.
19. Atkins JM, Pugh BR Jr, Timewell RM: Cardiovascular effects of topical beta-blockers during exercise. Am J Ophthalmol 1985;99:173-175.
20. Bacon PJ, Brazier DJ, Smith R, Smith SE: Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers. Br J Clin Pharmacol 1989;27:1-5.
21. Le Jeunne CL, Hugues FC, Dufier JL, Munera Y, Bringer L: Bronchial and cardiovascular effects of ocular topical β-antagonists in asthmatic subjects; comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol 1989;29:97-101.
22. Kashiwagi K, Makino F, Tsukahara S: Side effects of topical beta-blocker eyedrops on respiratory function in elderly healthy subjects. J Eye 1994;11:595-598.
23. Nakashima M, Watanabe I, Uematsu T, Nagashima S, Mizuno A, Matsuno H, et al: A double-blind evaluation of timolol and betaxolol ophthalmic solutions on blood pressure and pulse rate in healthy persons after exercise. Jpn J Clin Ophthalmol 1989;43:1777-1785.
24. Barnes PJ: Circadian variation in airway function. Am J Med 1985;79:5-9.
25. Neukirch F, Liard R, Segala C, Korobaeff M, Henry C, Cooremann J: Peak expiratory flow variability and bronchial responsiveness to methacholine. Am Rev Respir Dis 1992;146:71-75.
26. Townley RG, McGeady S, Bewtra S: The effect of beta adrenergic blockade on bronchial sensitivity to acetyl-beta-metacholine in normal and allergic rhinitis subjects. J Allergy Clin Immunol 1976;57:358-366.